{"preliminary_commentary":{"by_channel":{"x_thread":11,"youtube":2},"note":"Preliminary. Indexed podcasts, YouTube videos and X posts that name this trial so far. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this."},"free_build":{"available":true,"how":"POST https://www.erudio.com/api/trial-requests with {\"nct_id\": \"NCT04438083\", \"email\": \"<work email>\"}. The person who owns that inbox must confirm by the emailed link; agents cannot confirm. The result is the report's free public preview; the full report is still bought."},"commentary_summary":null,"drugs_tested":[["CTX130"]],"indication":"advanced clear cell renal cell carcinoma","name":"COBALT-RCC","nct_id":"NCT04438083","offer":{"currency":"USD","how":"Order at https://www.erudio.com/contact?report=cobalt-rcc-nct04438083. The price is an estimate of verified statements from the commentary indexed so far. Final coverage is set when the report is built. You never pay more than quoted: if the report is delivered at a smaller size, you pay that size's price, and anything paid above it is refunded. We build the report within 24 hours of confirming the order and deliver it when it passes our checks; if it cannot be built to our standard, nothing is charged.","price_rule":"Never more than quoted: the buyer pays the smaller of price_usd and the price the delivered edition is sold at.","price_usd":1250,"size":"standard","size_rule":"Standard: 151–300 verified statements, estimated at 14 per indexed commentary source"},"registry":{"acronym":null,"arms":[{"description":"Administered by IV infusion following lymphodepleting chemotherapy.","label":"CTX130","type":"EXPERIMENTAL"}],"collaborators":[],"completion_date":{"date":"2024-10-08","type":"ACTUAL"},"conditions":["Renal Cell Carcinoma"],"enrollment":{"count":19,"type":"ACTUAL"},"has_results":false,"interventions":[{"name":"CTX130","otherNames":[],"type":"BIOLOGICAL"}],"last_update":"2025-01-08","lead_sponsor":"CRISPR Therapeutics AG","official_title":"A Phase 1 Dose Escalation and Cohort Expansion Study of the Safety and Efficacy of Allogeneic CRISPR-Cas9-Engineered T Cells (CTX130) in Subjects With Advanced, Relapsed or Refractory Renal Cell Carcinoma With Clear Cell Differentiation","overall_status":"TERMINATED","phases":["PHASE1"],"primary_completion_date":{"date":"2024-10-08","type":"ACTUAL"},"primary_outcomes":[{"measure":"Part A (dose escalation): Incidence of adverse events","timeFrame":"From CTX130 infusion up to 28 days post-infusion"},{"measure":"Part B (cohort expansion): Objective response rate","timeFrame":"From CTX130 infusion up to 60 months post-infusion]"}],"references":[{"citation":"Dewulf J, Flieswasser T, Delahaye T, Vangestel C, Miranda A, de Haard H, Jacobs J, Smits E, Van den Wyngaert T, Elvas F. Site-specific 68Ga-labeled nanobody for PET imaging of CD70 expression in preclinical tumor models. EJNMMI Radiopharm Chem. 2023 Apr 24;8(1):8. doi: 10.1186/s41181-023-00194-3.","pmid":"37093350","type":"DERIVED"}],"start_date":{"date":"2020-06-16","type":"ACTUAL"},"study_type":"INTERVENTIONAL","title":"A Safety and Efficacy Study Evaluating CTX130 in Subjects With Relapsed or Refractory Renal Cell Carcinoma (COBALT-RCC)","url":"https://clinicaltrials.gov/study/NCT04438083"},"report":null,"schema_id":"erudio.trial_listing","schema_version":"3.2","state":"listed","state_text":"No report yet. It can be ordered.","url":"https://www.erudio.com/trials/cobalt-rcc-nct04438083"}